Woman reading the Dagens Industri newspaper

Press releases

Category
Year

Correction: Oncopeptides presents new data at the European Haematology Association meeting

May 12, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that new scientific data on melflufen has been accepted at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023. The data includes one clinical abstract on final efficacy and safety data from the phase 1/2 ANCHOR study, and one preclinical abstract on melflufen showing efficacy in association with decreased and mutated TP53 activity and enrichment of genes involved in DNA damage repair
Read more

Oncopeptides presents new data at the European Haematology Association meeting

May 11, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that final efficacy and safety data from the ANCHOR study has been accepted as a poster presentation at the European Hematology Association meeting (EHA) in Frankfurt, Germany on June 9, 2023
Read more

Oncopeptides publishes Q1 report 2023 Regulatory

May 4, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today publishes the report for the first quarter 2023
Read more

Oncopeptides issues warrants to utilize the first loan tranche from EIB Regulatory

May 3, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat haematological diseases, today announced that the company has decided to utilize the first tranche under the company's loan agreement with the European Investment Bank (EIB) and resolved on an issue of warrants
Read more

Invitation to presentation of the Q1 report 2023

May 2, 2023
Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on May 4
Read more

Oncopeptides publishes the 2022 Annual Report Regulatory

April 25, 2023
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces that the 2022 Annual Report has been published
Read more

Annual General Meeting in Oncopeptides AB (publ) Regulatory

April 21, 2023
The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 25 May 2023 at 3 p.m. Registration for attendees will commence at 2.30 p.m
Read more

Oncopeptides presents new scientific data at European Myeloma Network Meeting

April 20, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company presents new scientific data on melflufen at the European Myeloma Network meeting in Amsterdam on April 20. The data includes one abstract on health-related quality of life outcomes from the phase 3 OCEAN study, and one abstract from the phase 3 LIGHTHOUSE study
Read more

Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors

March 28, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced that the company has received a research grant of 3 MSEK from Sweden´s Innovation Agency (Vinnova), to explore the development of new treatment options for glioblastoma, an aggressive and incurable form of brain cancer. The grant enables exploratory research to better understand the potential of the PDC platform in solid tumors such as glioblastoma
Read more

Oncopeptides CSO released from custody Regulatory

March 10, 2023
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been informed that the company’s Chief Scientific Officer Jakob Lindberg was today released from custody. This, after being arrested on Wednesday March 8th, allegedly for unauthorized disclosure of inside information in October 2021
Read more